ClinicalTrials.gov record
Suspended Phase 2 Interventional

Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

ClinicalTrials.gov ID: NCT06240455

Public ClinicalTrials.gov record NCT06240455. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Placebo-controlled, Phase 2 Dose-range Study to Assess the Efficacy and Safety of WP1302 in Preventing Disease Relapse Following Methimazole Withdrawal in Subjects With Graves' Disease

Study identification

NCT ID
NCT06240455
Recruitment status
Suspended
Study type
Interventional
Phase
Phase 2
Lead sponsor
Worg Biotherapeutics Inc.
Other
Enrollment
176 participants

Conditions and interventions

Conditions

Interventions

  • WP1302 Drug
  • WP1302 placebo Drug
  • methimazole Combination Product

Drug · Combination Product

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 30, 2026
Primary completion
Mar 30, 2029
Completion
Sep 29, 2030
Last update posted
May 7, 2025

2026 – 2030

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
East Valley Diabetes and Endocrinology-Clinical Research, PLLC Hunt Arizona 85143
Alliance Research Institute Canoga Park California 22110
Paradigm Clinical Research Centers - Littleton Littleton Colorado 80120
BayCare Health System, Inc. Clearwater Florida 33759
Albuquerque Clinical Trials Inc Albuquerque New Mexico 87102
Cleveland Clinic Cleveland Ohio 44195
Clinical Research Solution LLC dba Endocrine and Psychiatry Center Houston Texas 77095

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06240455, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2025 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06240455 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →